NCT07101497View on ClinicalTrials.gov

Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 30, 2029

Conditions
Menin InhibitorsPost Hematopoietic Stem Cell TransplantationMaintenance TherapyAcute LeukemiaKMT2A RearrangementNPM1 MutationNUP98 Gene Rearrangement
Interventions
DRUG

BN104 monotherapy

BN104 will be started at 200 mg or 300mg, to a target dose of 400mg, twice daily, orally, 28 days a cycle, for a total of 24 to 36 cycles . When used in combination with posaconazoles and voriconazole, the dose of BN104 should be reduced by 50%.

Trial Locations (1)

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER

NCT07101497 - Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia | Biotech Hunter | Biotech Hunter